E-drug: Proposed deletions from WHO EDL
---------------------------------------------------------------------
Dear E-druggers,
We will soon commence revision of the Essential Drugs List for
Uganda in line with the requirements of the new Uganda Clinical
Guidelines 2003 and currently recommended therapeutic practice.
We would of course prefer to make any amendments
evidenced-based to the extent that this is possible.
We would thus be most interested to hear the evidence-based argu-
ments for and against the proposed deletions from the WHO EDL.
Currently the following items proposed for deletion from the WHO
EDL appear on the Uganda EDL 2001:
1.1 Ether
2.2 Codeine (as tab 30mg)
2.3 Colchicine (as tab 500 mcg)
5.0 Clonazepam (as tab 2mg and inj 500 mcg/mL)
6.1.1 Niclosamide (as tab 500mg)
6.2.2 Nalidixic acid (as tab/cap 500mg)
7.1 Ergotamine (as tab 1mg)
11.1 Polygeline (as IV infusion 3.5%)
11.2 Factor IX complex concentrate
11.2 Factor VIII concentrate
12.2 Procainamide (as tab 250mg)
12.3 Nifedipine (as tab 10mg and tab 20mg SR)
18.3.1 Medroxyprogesterone acetate (as depot injection 150mg/mL)
22.1 Ergometrine (as tab 200mcg)
22.2 Salbutamol (as tab 4mg and inj 1mg/mL)
25.1 Aminophylline (as tab 100mg and inj 25mg/mL)
25.1 Cromoglicic acid (as inhaler)
27 Calcium gluconate (as inj 100mg/mL)
Of these the following also appear in the Uganda Clinical Guidelines
2003 and are thus officially considered as still required/useful in
treating commonly occurring conditions:
2.2 Codeine (as alternative to dihydocodeine in stepped approach to
pain relief)
2.3 Colchicine (as alternative to NSAIDS in an acute attack of gout)
6.1.1 Niclosamide (as 2nd line drug for tapeworm)
6.2.2 Nalidixic acid (as alternative or 2nd line to ciprofloxacin in
bacillary dysentery)
7.1 Ergotamine (for migraine - used with propranolol)
11.1 Polygeline (as addition to IV fluid replacement solution in
treatment of severe burns)
12.3 Nifedipine (for sublingual use in eclampsia for treatment of
severe hypertension when hydralazine injection not available)
18.3.1 Medroxyprogesterone acetate (one option for long-term
contraception)
22.2 Salbutamol (for use in acute asthma [nebuliser or inhaler - tabs
when these not available]; in acute severe asthma [injection], in
severe bronchiolitis [tabs]; in very severe pneumonia [inhaler]
25.1 Aminophylline (for anaphylactic blood transfusion reactions [inj];
acute severe asthma [inj]
27 Calcium gluconate (as antidote to magnesium sulphate used in
eclampsia)
Chris Forshaw
Pharmaceutical Advisor
MoH / Danida Uganda Health Sector Programme Support
Room C114-C116, MoH Complex, Lourdel Road, Kampala
Tel: +256 41 235476 Fax: +256 41 235478
c/o Royal Danish Embassy, Box 11243, Kampala, Uganda
Tel: +256 77 760 176 (mobile)
Tel/Fax: +256 41 343 750 (home)
Email: chris.uhssp@utlonline.co.ug
--
To send a message to E-Drug, write to: e-drug@healthnet.org
To subscribe or unsubscribe, write to: majordomo@healthnet.org
in the body of the message type: subscribe e-drug OR unsubscribe e-drug
To contact a person, send a message to: e-drug-help@healthnet.org
Information and archives: http://www.essentialdrugs.org/edrug